Search Results 81-90 of 17255 for protein intake optimization

1. Mayo Clinic Q and A: Lifespan vs. healthspan

   We are trying to optimize the number of active, healthy and productive years that you enjoy. Lifespan refers to the total number of years a person lives ...

2. Neurosurgery - Clinical trials

   Cohort 1 includes blood collections for in vitro studies which are a component of NIH-funded Project 3 within the Mayo Clinic Pancreatic SPORE, “Optimal ...

3. A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors - Mayo Clinic

   serum M-protein > 0.5g/dl; and/or; urine M-protein ... o hemoglobin ≥9 g/dL. Phase 1b Expansion (Dose Optimization Part 4) ... requirements. Inability ...

4. Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... protein on a 24 hour urine protein electrophoresis ... Willing and able to comply with the requirements ...

5. Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... protein 4 [CTLA-4] agent, etc.) Another ... Known psychiatric or substance abuse disorders that would interfere ...

6. A Study of Investigational Immunotherapy to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, with or without Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Hematologic Malignancies - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... protein ≥ 0.5 g/dl), OR urine M-protein ≥ 200 ... Requirement for daily supplemental oxygen therapy.

7. Study of Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... The purpose of this study is to assess how well rituximab and latent membrane protein ... All institutional, ...

8. A Study To Evaluate The Long-Term Safety And Effectiveness Of Ubenimex In Patients With Pulmonary Arterial Hypertension - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... requirements during study EIG-UBX-001; Agrees ... protein-coupled receptor, BLT1. LTB4 activated ...

9. Coronavirus Disease 2019 (COVID-19) Clinical Trials - Mayo Clinic Research

   The purpose of this study is to assess levels of caffeine intake ... optimal protective potential of the ... protein antibodies, and to identify microRNA ...

10. Cardiac resynchronization therapy - Type - Mayo Clinic

    Optimized implementation of cardiac resynchronization therapy: A call for action for referral and optimization of care. ... Admissions Requirements · Degree ...